Monitor NDA resubmission timeline by end of 2026 and FDA decision by mid-2027. Key catalysts include detailed data presentation at upcoming medical conference and potential accelerated approval given positive Phase 3 results. The 97% rollover to HELIOS extension suggests strong patient compliance.
Price Chart
Executive Summary
Disc Medicine announced positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints with statistical significance. The company plans to resubmit an NDA to the FDA by end of 2026 with a decision anticipated by mid-2027, representing a potential breakthrough in a rare disease with high unmet need.
Key Facts
- APOLLO Phase 3 trial (n=183) met both co-primary endpoints: PPIX reduction (-41.4% vs placebo, p<0.0001) and increased time in light during month 6 (+12.2 hours vs placebo, p=0.0010)
- All secondary endpoints met, including 71% reduction in phototoxic reactions (p<0.0001) and improved quality-of-life scores (PGIC/PGIS both p<0.0001)
- NDA resubmission planned by end of 2026; FDA decision anticipated by mid-2027
- Bitopertin was generally well-tolerated; dizziness (50%) was most common TEAE, all mild/moderate and transient; no Grade 4+ TEAEs
- 97% of patients rolled over to HELIOS long-term extension trial
Financial Impact
Potential first-in-class disease-modifying therapy for EPP, a rare disease with ~6K diagnosed patients in the US; company estimates $2B+ US addressable market for EPP
Risk Factors
- Regulatory risk: FDA may require additional data or raise concerns during NDA review despite positive Phase 3 data
- Competition: Existing approved therapy (Scenesse/afamelanotide) already on market; bitopertin would need to demonstrate differentiation
- Commercial execution risk: Launch expected November 2026 requires successful market access and physician adoption
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424649 |
| Document: d156263dex992.htm | 0001193125-26-424649 |
| Document: d156263dex991.htm | 0001193125-26-424649 |
| Document: 0001193125-26-424649-index-headers.html | 0001193125-26-424649 |
| Document: 0001193125-26-424649-index.html | 0001193125-26-424649 |
| Document: 0001193125-26-424649.txt | 0001193125-26-424649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $74.95 | awaiting T+20 | — | $74.51 (+0.59%) |
Oct 21, 2026 4d ago | 424B5 | $75.03 | awaiting T+20 | — | $74.51 (+0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 19, 2026 6d ago | 424B5 | $79.48 | awaiting T+20 | — | $74.51 (+6.25%) |
Oct 19, 2026 6d ago | 144 | $79.48 | awaiting T+20 | — | $74.51 (−6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers